💨 Abstract

Eli Lilly's stock dropped after CVS Health excluded Zepbound, a blockbuster weight-loss drug, from its standard formulary, favoring competitors Wegovy and Saxenda. This could affect access for patients who can't afford the drug out-of-pocket. CVS Health will sell Wegovy at a discount for uninsured patients.

Courtesy: wtop.com

Summarized by Einstein Beta 🤖